Search Results - "Maegawa, Rodrigo"

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin, Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Anderson, Adrienne, Boardman, Alexander P., Weber, Augustine, Avigan, David, Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey, Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Ritz, Jerome, Streicher, Howard, Ball, Edward D., Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell…”
Get full text

Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review by Atallah, Ehab, Saini, Lovneet, Maegawa, Rodrigo, Rajput, Tanvi, Corbin, Regina, Viana, Ricardo

“…Background: ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia…”
Get full text

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis by Radich, Jerald P, Wall, Matthew, Branford, Susan, Campbell, Catarina D, Chaturvedi, Shalini, DeAngelo, Daniel J, Deininger, Michael, Guinney, Justin, Hochhaus, Andreas, Hughes, Timothy P, Kantarjian, Hagop M, Larson, Richard A, Li, Sai, Maegawa, Rodrigo, Mishra, Kaushal, Obourn, Vanessa, Pinilla-Ibarz, Javier, Purkayastha, Das, Sadek, Islam, Saglio, Giuseppe, Shrestha, Alok, White, Brian S, Druker, Brian J

“…Tyrosine kinase inhibitor therapy revolutionized chronic myeloid leukemia treatment and showed how targeted therapy and molecular monitoring could be used to…”
Get full text

Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective by Atallah, Ehab L, Maegawa, Rodrigo, Latremouille-Viau, Dominick, Rossi, Carmine, Guérin, Annie

“…Tyrosine kinase inhibitors (TKIs) are the standard-of-care treatment for chronic myeloid leukemia in chronic phase (CML-CP). Despite advances in therapy, there…”
Get full text

Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States by Atallah, Ehab L, Maegawa, Rodrigo, Latremouille-Viau, Dominick, Rossi, Carmine, Guérin, Annie, Wu, Eric Q, Patwardhan, Pallavi

“…Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia in chronic phase (CML-CP), a sizeable proportion of patients with…”
Get full text

Triple-Negative Breast Cancer: Unique Biology and Its Management by Maegawa, Rodrigo O. B., Tang, Shou-Ching

“…Triple-negative breast cancer is defined by the lack of expression of estrogen-receptor, progesterone-receptor, and HER-2/neu. It primarily, but not…”
Get full text

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT) by Davids, Matthew S., Kim, Haesook T., Costello, Caitlin L., Herrera, Alex F., Locke, Frederick L., Maegawa, Rodrigo O., Savell, Alexandra, Mazzeo, Michael, Avigan, David E., Chen, Yi-Bin, Nikiforow, Sarah, Ho, Vincent T., Cutler, Corey S., Alyea, Edwin P., Bachireddy, Pavan, Wu, Catherine J., Streicher, Howard, Ball, Edward D, Bashey, Asad, Soiffer, Robert J., Armand, Philippe

“…Patients (pts) with relapsed hematologic malignancies (HM) after alloHCT are a unique population, given the potential to harness a dormant graft-vs.-tumor…”
Get full text

Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample by Souza, Ricardo L.R., Mikami, Liya R., Maegawa, Rodrigo O.B., Chautard-Freire-Maia, Eleidi A.

“…The genetic variation of human butyrylcholinesterase has been associated with height, body mass index, Alzheimer’s disease, and response to xenobiotic agents…”
Get full text

Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings by Maegawa, Rodrigo O. B., Hussain, Sajid, Danila, Daniel C., Teruya-Feldstein, Julie, Maki, Robert G., O'Connor, Owen A.

Get full text

Targeted Literature Review of Patient Reported Outcomes (PROs) in Chronic Myeloid Leukemia (CML) Patients Receiving Second and Later Lines of Treatment by Zhang, Shiyu, Maegawa, Rodrigo, Nandal, Savita, Patwardhan, Pallavi

“…Background: Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic CML in the last several years; however, the failure rates associated…”
Get full text

Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices by Patel, Pareshkumar, Raju, Aditya, Coutinho, Anna, Maegawa, Rodrigo, Lunacsek, Orsolya, Deyoung, Kathryn, Iorga, Serban, Cao, Xiting

“…BACKGROUND: Current treatment guidelines recommend tyrosine kinase inhibitors (TKIs) as first-line and second-line treatment options for patients with chronic…”
Get full text

Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review by Allan, John N., Kipps, Thomas J., Bokun, Alex, Maegawa, Rodrigo, O'Brien, Susan M.

Get full text

CLL-481 Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review by Allan, John N., Kipps, Thomas J., Bokun, Alex, Maegawa, Rodrigo, O'Brien, Susan M.

“…Ibrutinib is a first-in-class, once-daily covalent Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of patients with chronic lymphocytic…”
Get full text

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy by Atallah, Ehab L., Maegawa, Rodrigo, Latremouille-Viau, Dominick, Rossi, Carmine, Guerin, Annie, Patwardhan, Pallavi

“…Introduction: Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML), there remains a sizeable proportion of patients…”
Get full text

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI) by Sasaki, Koji, Mauro, Michael, Levy, Moshe Yair, Atallah, Ehab L., Koller, Paul B., Maegawa, Rodrigo, Damon, Andrea, Kumar, Julie, Khan, Mahmudul, Cortes, Jorge E.

Get full text

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database by Mukherjee, Sudipto, Chen, Chi-Chang, Gorritz, Magdaliz, Sadek, Islam, Iorga, Serban, Zhou, Zifan, He, Jing, Maegawa, Rodrigo, Damon, Andrea, Ferreira, Germano, Jadhav, Kejal

Get full text

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) by Mukherjee, Sudipto, Cao, Xiting, Sadek, Islam, Maegawa, Rodrigo, Latremouille-Viau, Dominick, Pivneva, Irina, Guérin, Annie, Smith, B. Douglas

“…Introduction: Second-generation (2G) TKIs have shown better efficacy than first-generation (1G) TKI in patients (pts) with Ph+ CML-CP. However, real-world…”
Get full text

Poster: CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US) by Kota, Vamsi, Maegawa, Rodrigo, Latremouille-Viau, Dominick, Jadhav, Kejal, Rossi, Carmine, Guérin, Annie, Iorga, Şerban

Get full text

CML-475 Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US) by Kota, Vamsi, Maegawa, Rodrigo, Latremouille-Viau, Dominick, Jadhav, Kejal, Rossi, Carmine, Guérin, Annie, lorga, Şerban

Get full text

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations by Andorsky, David, Tomassetti, Sarah, Deutsch, Yehuda E., Broun, E Randolph, Issa, Ghayas C., Levy, Moshe Y., Deininger, Michael W., Maegawa, Rodrigo, Shrestha, Alok, Mauro, Michael J.

“…Chronic myeloid leukemia (CML) is driven by the constitutively active BCR-ABL1 tyrosine kinase. Several adenosine triphosphate (ATP)-competitive tyrosine…”
Get full text